ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0083

COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network

Amy Mudano1, Fenglong Xie1, Patrick Stewart2, Lesley Jackson3, Maria Danila3, Kelly Gavigan4, William Benjamin Nowell5, Shilpa Venkatachalam6 and Jeffrey Curtis7, 1Illumination Health, Hoover, AL, 2Bendcare, Boca Raton, FL, 3University of Alabama at Birmingham, Birmingham, AL, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Global Healthy Living Foundation, Nyack, NY, 6Global Healthy Living Foundation, New York, NY, 7Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Sub-optimal COVID-19 vaccine uptake by patients with autoimmune conditions is an area of concern to many rheumatologists and other providers. It is important to understand which patients are receiving vaccines and the reasons why some are not. We surveyed a large convenience sample of patients in a network of rheumatology practices to ascertain vaccine use and hesitancy.

Methods: A tablet-based, electronic survey tool was used in a network of 101 rheumatology providers with over 250,000 patients. Providers in the network employ a tablet in their office as part of routine care to collect patient survey and outcome data directly from patients on their arrival for appointments. Patients were given this tablet with surveys that included a short series of COVID-19 vaccine-related questions between September 2021 and June 2022. Patients were asked about their COVID-19 vaccine status for both primary vaccine series and vaccine booster, to provide a time estimate on when they planned to start or complete their vaccination series, and reasons that they might not receive their COVID-19 vaccine or booster. We provide a descriptive analysis of vaccine receipt and reasons for hesitancy in this group.

Results: A total of 86,540 patients provided an answer to questions about their vaccination status (Table 1). Of those, 76% reported they had been fully vaccinated with the primary series (i.e., received the first 2 COVID-19 shots or the one-dose Johnson & Johnson vaccine). Another 2% reported that they were partially vaccinated (i.e., still had one shot remaining in their primary series) and an additional 6% said they had not received their first vaccine shot yet, but planned to. The remaining 16% replied that they did not intend to get a COVID-19 vaccination at this time. Over 50% of those who were fully vaccinated had received the Pfizer vaccine, followed closely by Moderna at 41% and 6% received the one-dose Johnson & Johnson vaccine. A total of 45,760 fully-vaccinated patients were asked if they had received a supplemental COVID-19 vaccine dose (booster) and 70% replied that they had received the booster. When asked about concerns with the COVID-19 vaccine and reasons they might not get a COVID-19 booster (Table 2), most patients cited concerns about vaccine safety (34%) or side effects (25%) with the primary series. While concerns about safety (21%) and side effects (15%) were also cited as reasons for hesitancy in receiving the booster, the biggest reason cited was that they had not been told by their doctor to get an additional dose (33%).

Conclusion: In a network of rheumatology practices, more than 75% reported being fully vaccinated with a primary vaccine series and 70% reported also having a supplemental COVID-19 dose (booster). Concerns about effectiveness and safety were cited as primary barriers to receiving the COVID-19 vaccine and reasons to not get the booster, while recommendation from the physician was also a big factor with the booster. Despite its wide availability and need for the COVID-19 vaccine in these patients, hesitancy about the vaccine remains a persistent concern.

Supporting image 1

Supporting image 2


Disclosures: A. Mudano, None; F. Xie, Bendcare LLC; P. Stewart, None; L. Jackson, BHOF; M. Danila, UCB, Pfizer; K. Gavigan, None; W. Nowell, Global Healthy Living Foundation, AbbVie Inc., Amgen, Eli Lilly; S. Venkatachalam, None; J. Curtis, Amgen, Bristol-Myers Squibb (BMS), CorEvitas, IlluminationHealth, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, UCB, Aqtual, Bendcare, FASTER, GlaxoSmithKlein (GSK), Labcorp, Scipher, Setpoint, United Rheumatology, AbbVie, ArthritisPower.

To cite this abstract in AMA style:

Mudano A, Xie F, Stewart P, Jackson L, Danila M, Gavigan K, Nowell W, Venkatachalam S, Curtis J. COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/covid-19-vaccine-uptake-and-reasons-for-hesitancy-in-a-large-rheumatology-practice-network/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-vaccine-uptake-and-reasons-for-hesitancy-in-a-large-rheumatology-practice-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology